These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1914229

  • 1. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome.
    Heslan JM, Branellec AI, Pilatte Y, Lang P, Lagrue G.
    Clin Exp Immunol; 1991 Oct; 86(1):157-62. PubMed ID: 1914229
    [Abstract] [Full Text] [Related]

  • 2. Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Nephron; 2001 Feb; 87(2):111-7. PubMed ID: 11244304
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-15 and interleukin-12 have an additive effect on the release of vascular permeability factor by peripheral blood mononuclear cells in normals and in patients with nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Clin Nephrol; 1999 Jul; 52(1):10-8. PubMed ID: 10442490
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome.
    Maruyama K, Tomizawa S, Seki Y, Arai H, Kuroume T.
    Nephron; 1992 Jul; 62(1):27-30. PubMed ID: 1436287
    [Abstract] [Full Text] [Related]

  • 5. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Nephron; 1998 Jul; 78(4):403-9. PubMed ID: 9578066
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Am J Nephrol; 1999 Jul; 19(1):21-7. PubMed ID: 10085445
    [Abstract] [Full Text] [Related]

  • 7. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Nephron; 1999 Jul; 82(1):32-8. PubMed ID: 10224482
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Nephron; 2000 Jun; 85(2):127-33. PubMed ID: 10867518
    [Abstract] [Full Text] [Related]

  • 9. Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome.
    Tomizawa S, Maruyama K, Nagasawa N, Suzuki S, Kuroume T.
    Nephron; 1985 Jun; 41(2):157-60. PubMed ID: 3876517
    [Abstract] [Full Text] [Related]

  • 10. Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF).
    Kondo S, Yoshizawa N, Kusumi Y, Takeuchi A, Torikata C.
    Clin Nephrol; 1999 Nov; 52(5):278-84. PubMed ID: 10584990
    [Abstract] [Full Text] [Related]

  • 11. Vascular permeability increasing factor (VPF) in IgA nephropathy.
    Bakker WW, Beukhof JR, van Luijk WH, van der Hem GK.
    Clin Nephrol; 1982 Oct; 18(4):165-7. PubMed ID: 7140031
    [Abstract] [Full Text] [Related]

  • 12. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Nephron; 1997 Oct; 77(2):212-8. PubMed ID: 9346389
    [Abstract] [Full Text] [Related]

  • 13. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF.
    Claffey KP, Senger DR, Spiegelman BM.
    Biochim Biophys Acta; 1995 Jan 05; 1246(1):1-9. PubMed ID: 7811723
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.
    Sioussat TM, Dvorak HF, Brock TA, Senger DR.
    Arch Biochem Biophys; 1993 Feb 15; 301(1):15-20. PubMed ID: 8442657
    [Abstract] [Full Text] [Related]

  • 15. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.
    Matsumoto K.
    Nephron; 1997 Feb 15; 75(2):154-9. PubMed ID: 9041534
    [Abstract] [Full Text] [Related]

  • 16. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation.
    Walter DH, Hink U, Asahara T, Van Belle E, Horowitz J, Tsurumi Y, Vandlen R, Heinsohn H, Keyt B, Ferrara N, Symes JF, Isner JM.
    Lab Invest; 1996 Feb 15; 74(2):546-56. PubMed ID: 8780172
    [Abstract] [Full Text] [Related]

  • 17. Increased IL-12 release by monocytes in nephrotic patients.
    Matsumoto K, Kanmatsuse K.
    Clin Exp Immunol; 1999 Aug 15; 117(2):361-7. PubMed ID: 10444271
    [Abstract] [Full Text] [Related]

  • 18. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.
    Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF.
    Cancer Res; 1993 Jun 15; 53(12):2912-8. PubMed ID: 8504432
    [Abstract] [Full Text] [Related]

  • 19. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.
    Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J.
    J Clin Invest; 1989 Nov 15; 84(5):1470-8. PubMed ID: 2478587
    [Abstract] [Full Text] [Related]

  • 20. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.
    Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF.
    Cancer Res; 1995 Jan 15; 55(2):360-8. PubMed ID: 7812969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.